Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosis.

Authors

Ming-Hui Tai, Brandon Brown, Riley Taiji, Ariane Faucher, Francis Vekeman, Raluca Ionescu-Ittu, Abhijit Gadkari

Published in

Multiple sclerosis journal - experimental, translational and clinical. Volume 12. Issue 3. Pages 20552173261464369. Epub Aug 08, 2026.

Abstract

Treatment schedule complexity and route of administration may influence patient adherence and persistence. Limited real-world evidence exists comparing these outcomes across treatments for multiple sclerosis (MS).
To examine 18- and 24-month adherence/persistence of ofatumumab (OMB) and other approved disease-modifying therapies (DMTs).
Optum Clinformatics® Data Mart data were used to identify adult patients with MS who initiated treatment with an approved DMT from August 20, 2019, to December 31, 2023. Patients were stratified into four treatment groups: OMB, infusion DMTs, oral DMTs, and other injectable DMTs.
After propensity score matching, adherence to OMB was significantly higher than to oral DMTs (18 months: 73% vs. 51% [p < .001]; 24 months: 69% vs. 47% [p < .001]) and was also higher with OMB than with other injectable agents (18 months: 74% vs. 40% [p < .001]; 24 months: 70% vs. 35% [p < .001]). Adherence to OMB and infusion DMTs was comparable (18 months: 74% vs. 70% [p = .31]; 24 months: 70% vs. 65% [p = .24]). Similar patterns were observed for persistence between the groups.
These findings suggest OMB is a convenient, effective, self-administered alternative to infusion therapies.

PMID:
42572537
Bibliographic data and abstract were imported from PubMed on 10 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.